1. Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection
- Author
-
Victoria Shi, Erika Benko, J. Shawn Justement, Paul A. Wender, Kathleen R. Gittens, Colin Kovacs, Michael C. Sneller, Susan Moir, Tae-Wook Chun, Erin D Huiting, Anthony S. Fauci, and Jana Blazkova
- Subjects
0301 basic medicine ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Major Articles and Brief Reports ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Secondary Prevention ,Humans ,Immunology and Allergy ,Medicine ,Longitudinal Studies ,030212 general & internal medicine ,business.industry ,Drug holiday ,Antiretroviral therapy ,Lymphocyte Subsets ,Clinical trial ,030104 developmental biology ,Infectious Diseases ,Anti-Retroviral Agents ,Treatment interruption ,Immunology ,HIV-1 ,business ,Early phase ,Lymphocyte subsets - Abstract
Therapeutic strategies for achieving sustained virologic remission are being explored in human immunodeficiency virus (HIV)–infected individuals who began antiretroviral therapy (ART) during the early phase of infection. In the evaluation of such therapies, clinical protocols should include analytical treatment interruption (ATI); however, the immunologic and virologic impact of ATI in individuals who initiated ART early has not been fully delineated. We demonstrate that ATI causes neither expansion of HIV reservoirs nor immunologic abnormalities following reinitiation of ART. Our findings support the use of ATI to determine whether sustained virologic remission has been achieved in clinical trials of individuals who initiated ART early during HIV infection.
- Published
- 2019